|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.13 USD | +0.27% |
|
-.--% | - |
| 28/25/28 | Verve Therapeutics, Inc.(NasdaqGS:VERV) dropped from S&P Biotechnology Select Industry Index | CI |
| 28/25/28 | Verve Therapeutics, Inc.(NasdaqGS:VERV) dropped from S&P Global BMI Index | CI |
| Market Cap | 99Cr 87Cr 80Cr 75Cr 140.94Cr 9.38TCr 141.79Cr 952.36Cr 369.1Cr 4.62TCr 373.17Cr 365.17Cr 16TCr | P/E 2023 |
-4.47x | P/E 2024 | -2.4x |
|---|---|---|---|---|---|
| Enterprise Value | 54Cr 47Cr 44Cr 41Cr 77Cr 5.09TCr 77Cr 517.16Cr 200.43Cr 2.51TCr 202.64Cr 198.3Cr 8.71TCr | EV / Sales 2023 |
4,64,30,598x | EV / Sales 2024 | 7,17,743x |
| Free-Float |
-
| Yield 2023 * |
-
| Yield 2024 | - |
Last Transcript: VERE THER
| 1 day | +0.27% |
| 1 year | 10.9 |  | 11.34 |
| 3 years | 2.86 | | 21.04 |
| 5 years | 2.86 | | 78 |
| 10 years | 2.86 | | 78 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jonathan Haug
PSD | President | - | 25/07/2025 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 25/25/25 | Tender | Company | 1,23,46,828 | 14.5834% | ||
| 25/25/25 | Tender | Chief Technology Officer | 3,92,157 | 0.4632% | ||
| 25/25/25 | Issuer sale | Director | 1,78,339 | 0.2106% |
| 2023 | 2024 | |
|---|---|---|
| Net sales | 11.76 10.25 9.49 8.89 16.67 1.11T 16.77 112.64 43.65 546.09 44.14 43.19 1.9T | 32.33 28.19 26.11 24.44 45.84 3.05T 46.12 309.73 120.04 1.5T 121.36 118.76 5.21T |
| Net income | -20Cr -17Cr -16Cr -15Cr -28Cr -1.89TCr -29Cr -191.66Cr -74Cr -929.2Cr -75Cr -73Cr -3.23TCr | -20Cr -17Cr -16Cr -15Cr -28Cr -1.87TCr -28Cr -190.36Cr -74Cr -922.89Cr -75Cr -73Cr -3.2TCr |
| Net Debt | -55Cr -48Cr -44Cr -42Cr -78Cr -5.18TCr -78Cr -525.97Cr -203.84Cr -2.55TCr -206.09Cr -201.67Cr -8.85TCr | -45Cr -40Cr -37Cr -34Cr -64Cr -4.29TCr -65Cr -435.21Cr -168.67Cr -2.11TCr -170.53Cr -166.87Cr -7.33TCr |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- VERV Stock
Select your edition
All financial news and data tailored to specific country editions
